Gapping up
In reaction to strong earnings/guidance:
- WWE +13.4%, PBCT +10%, TPH +7.5%, EW +7.4%, ALV +7.4%, VCRA +5.6%, B +5.1%, VICR +4%, MMSI +2.8%, AXP +2.8%, ASB +2.2%, BOOM +1.9%, VRSN +1.8%, TRTN +1.6%, COF +1.5%, RHI +1.1%, VZ +1.1%, SNY +0.8%
Other news:
- MESO +82.2% (reports 83% survival in COVID-19 patients with moderate/severe acute respiratory distress syndrome treated in New York with Cell Therapy Remestemcel-L)
- CHK +16.2% (adopts shareholder rights plan)
- PSTI +15.8% (secures EUR 50 mln non-dilutive financing from the european investment bank to support its COVID-19 project and phase 3 studies)
- EBS +7.8% (Emergent BioSolutions agrees to be U.S. manufacturing partner for Johnson & Johnson's (JNJ) lead vaccine candidate for COVID-19)
- DVAX +4.1% (indicated higher after confirming will report first quarter 2020 financial results on Thursday, May 7, 2020, after the U.S. financial markets close)
- ZM +3.8% (to join the NASDAQ-100 Index beginning April 30)
- MR +1.2% (provides preliminary Q1 production update)
- LLY +1% (Eli Lilly and Innovent reports NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with ALIMTA)
Analyst comments:
- OII +3.3% (upgraded to Buy from Neutral at Citigroup)
- EXPE +2.6% (upgraded to Mkt Outperform from Mkt Perform at JMP Securities)
- EBAY +2.1% (upgraded to Buy from Hold at Stifel)